Experiencia en el tratamiento de satelitosis y metástasis cutáneas en tránsito de melanoma con interleucina 2 intralesional
Authors:
- G. CarreteroGCG. Carretero
- 1 September 2009
- journal article
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 100 (7) , 571-585
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Efficacy of Repeat Isolated Limb Perfusions With Tumor Necrosis Factor α and Melphalan for Multiple In-Transit Metastases in Patients with Prior Isolated Limb Perfusion FailureAnnals of Surgical Oncology, 2005
- ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of cutaneous malignant melanomaAnnals of Oncology, 2005
- One Hundred Consecutive Isolated Limb Perfusions With TNF-α and Melphalan in Melanoma Patients With Multiple In-Transit MetastasesAnnals of Surgery, 2004
- Hyperthermic Isolated Limb Perfusion With Low-Dose Tumor Necrosis Factor-α and Melphalan for Bulky In-Transit Melanoma MetastasesAnnals of Surgical Oncology, 2004
- Is there a Role for Isolated Limb Perfusion With Tumor Necrosis Factor in Patients With Melanoma?Annals of Surgical Oncology, 2004
- Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastasesBritish Journal of Cancer, 2003
- Locoregional cutaneous metastasis in patients with therapeutic lymph node dissection for malignant melanoma: risk factors and prognostic impactMelanoma Research, 2002
- Final Version of the American Joint Committee on Cancer Staging System for Cutaneous MelanomaJournal of Clinical Oncology, 2001
- Structure and expression of a cloned cDNA for human interleukin-2Nature, 1983
- Selective in Vitro Growth of T Lymphocytes from Normal Human Bone MarrowsScience, 1976